Year
2025202420232021202020192018201720162015201420132012201120102009200820072006200520042003200220012000
Edition number
№7 / 2022
Press Release
10-12
REVIEWS
S.A. Volchenkov, L.V. Filatova, S.V. Lyubimov, I.S. Zyuzgin, S.S. Elkhova, A.A. Zverkova, I.V. Ishmatova, T.Yu. Semiglazova
Modern aspects of nutritional support during hematopoietic stem cell transplantation: review, experience of the N.N. Petrov National Medical Research Center of Oncology14-22
S.S. Elkhova, L.V. Filatova, I.S. Zyuzgin, S.A. Volchenkov, A.K. Kovyazin, M.S. Motalkina, Yu.A. Chudinovskikh, T.Yu. Semiglazova
Approaches to the mobilization of hematopoietic stem cells: a literature review23-28
A.I. Tseluiko, V.F. Semiglazov, A.G. Kudaibergenova, A.S. Artemyeva, R.M. Paltuev, R.V. Donskikh, R.S. Pesotsky, P.V. Krivorotko
Clinical immunology of breast cancer29-36
Sh.R. Abdulaeva, T.Yu. Semiglazova, A.S. Artemyeva, A.G. Kudaibergenova, S.M. Sharashenidze, A.I. Tseluyko, R.M. Paltuev, V.V. Semiglazov, P.V. Krivorotko, V.F. Semiglazov
Predictive and prognostic role of tumor-infiltrating lymphocytes (TILs) in early triple-negative breast cancer37-42
R.S. Pesotsky, V.F. Semiglazov, A.I. Tseluyko, M.D. Sokolova, V.V. Mortada, T.T. Tabagua, P.V. Krivorotko
Treatment of HER2-positive early (minimal) breast cancer43-48
He Mingze, Zeng Zitong
Modern approaches to the treatment of muscle-invasive bladder cancer49-52
ORIGINAL ARTICLES
S.A. Protsenko, G.M. Teletaeva, D.Kh. Latipova, A.I. Semenova, A.V. Novik, Yu.I. Komarov, Sh.A. Dzhalilova, A.Yu. Malygin, E.A. Degtiareva
The use of pazopanib in the treatment of disseminated soft tissue sarcoma: personal experience53-56
A.V. Andreeva, M.B. Antsiferov
Evaluation of the effectiveness of combination therapy with somatostatin analogues and D2-dopamine receptor agonists in the treatment of persistent or recurrent course of Cushing’s disease57-65
O.D. Guryeva, M.I. Savelyeva, T.T. Valiev
Influence of pharmacogenetic parameters on clinical variants of methotrexate toxicity in acute lymphoblastic leukemia in children66-70
I.V. Poddubnaya, N.A. Ognerubov, T.S. Antipova
Thymus hyperplasia after lymphoma drug therapy: the role of PET/CT71-77
N.P. Belyak, R.V. Orlova, S.I. Kutukova, Yu.V. Pelipas, A.V. Androsova, N.V. Zhukova
Pathological regression as an indicator of the effectiveness of perioperative FLOT/FOLFOX in patients with resectable gastric cancer78-82
A.V. Androsova, R.V. Orlova, A.K. Ivanova, N.P. Belyak, S.I. Kutukova, A.A. Varankina
The role of some factors of systemic inflammation in the course of gastrointestinal neuroendocrine tumors83-88
I.B. Zhurtova, L.V. Elgarova, A.M. Gubachikova
Immune-mediated endocrine adverse events during treatment with immune checkpoint inhibitors: a clinical case of nivolumab-induced thyroiditis90-94
Yu.I. Khruleva, I.I. Amergulov, N.V. Likhodey, A.S. Dzyuba, Yu.P. Sych, M.G. Pavlova
Multiple thyroid carcinoma and other long-term endocrine consequences of chemoradiotherapy for medulloblastoma: a clinical case95-99
